ReviewImmunoTargets and therapy2024
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer.
Review in ImmunoTargets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Tissue-resident memory T-cell expressions and their prognostic role in head and neck squamous cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model ofCancer biology & therapy · 2026Article
- Ultrasound controllable and antigen-independent killing viaMolecular therapy. Oncology · 2026Article
- Manganese-potentiated cGAS-STING activation with ATM/PRMT5 inhibition remodels the immunosuppressive microenvironment in osteosarcomaBioactive materials · 2026Article
- CSF1R inhibitor C19 for glioma immunotherapy enabled by brain-targeting liposomal delivery.Acta pharmacologica Sinica · 2026Article
- The LEF1-LAG3 axis regulates CD4Parasites & vectors · 2026Article
- IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8Journal of gastroenterology and hepatology · 2026Article
- CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model.Stem cell research & therapy · 2026Article
- Not so cold after all: tumor infiltrating CD8+ T cells in EBV-positive Burkitt lymphoma are quiescent, not exhausted.bioRxiv : the preprint server for biology · 2026Article
- T Cell Receptor Co-Stimulation Through Magnetogenetic Tools: A Platform for Wireless Rewiring of Cellular Signaling.ACS omega · 2026Article
- Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2026Article
- Integrative Proteogenomic Analysis Identifies Genetically Supported Plasma Proteins, Metabolites, and Pathways in Glaucoma.Investigative ophthalmology & visual science · 2026Article
- Plasma extracellular vesicles reflect response and prognosis in patients with breast cancer undergoing neoadjuvant treatment.Breast cancer research : BCR · 2026Article
- Dual-Pronged Lipid Nanocarriers Promote Immunotherapy for TNBC by Inducing Immunogenic Cell Death and Activating Lymphoid Immune Cells.Research (Washington, D.C.) · 2026Article
- Immunophenotypic Profiling of Lymphocyte Subsets in Children and Adolescents With Acute Lymphoblastic Leukaemia: Immune Dysregulation Before and After Remission.Journal of immunology research · 2026Article
- Single-cell transcriptome analysis reveals regulatory programs associated with tumor resistance during immunotherapy in colorectal cancer.International journal of surgery (London, England) · 2026Article
- An exploration of GuaLouQuMaiWan related novel prognostic model and search for potential compound pachymic acid in bladder cancer.Frontiers in oncology · 2026Article
- Hyperglycemia Induced in Sprague-Dawley Rats Modulates the Expression of CD36 and CD69 During Wound Healing.International journal of molecular sciences · 2025Article
- Perioperative Profiles of Immune Cells in Patients with Postoperative Delirium After Cardiac Surgery with Cardiopulmonary Bypass.Biomedicines · 2025Article
- NFATc1 regulates LAG3+CD8+ T cells in the spleen of mice infected with Plasmodium yoelii NSM.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy utilizing T cells that attack tumors is a promising strategy for treatment, but immune suppressive T cell subsets, such as regulatory T cell (Treg), and immune checkpoint molecules, including programmed death-1 (PD-1), can suppress the intensity of a T cell immune reaction and thereby impair tumor clearance. Cluster of differentiation 69 (CD69), known as an early leukocyte activation marker, can be used as a measure or early marker of T cell activation. In recent years, the functions of CD69 in the regulation of Treg/Th17 (T helper cell 17) differentiation and in the tissue retention of T cells have attracted considerable interest. These functions are related to the role of CD69 in immune suppression in tumor environments (TME). In this review, we first summarized current perspectives in the biological function of CD69 and demonstrated that CD69 acts as a regulator of T cell activation, differentiation, retention, and exhaustion. Then, we discussed recent advances in understanding of CD69 deficiency and anti-CD69 antibody administration and shed light on the value of targeting on CD69 for cancer immunotherapy and prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.